Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (948)	12/28/1998 10:16:00 PM
From: ubrx	Read Replies (1) \| Respond to of 1477

Miljenko, To the best of my knowledge the complete reasons for the suspension of the Fiblast N.A. stroke trials have never been fully explained. As you know, the European Stroke trials continue. I would appreciate it if you post any information you come across. I agree that the indications of PVD (peripherial vascular disease) and CAD (coronary artery disease) still hold much potential for Fiblast and VEGF121. Hopefully clinical trials will begin with the next few months. Jim

To: Miljenko Zuanic who wrote (948)	12/28/1998 11:39:00 PM
From: Rudy Saucillo	Read Replies (1) \| Respond to of 1477

MZ, the only info that I've seen (which of course is public info) is that there was a greater incidence of mortality in the Fiblast arm vs. placebo in the US trial. The safety committee has not observed this in the Euro stroke trial which was allowed to continue. Scios has pointed out that the greater incidence of mortality has not been directly tied to Fiblast use. Rudy